24 results
Thumbnail

D2.182 - Low-dose oral food challenge (OFC) in a pediatric day-care hospital: a pre-immunotherapy approach for managing nut-allergies in children

Thumbnail

D2.183 - Assessment of Incidence and Onset of Eosinophilic Esophagitis during the clinical development of Peanut (Arachis hypogaea) Allergen Powder-dried non-fat protein for oral immunotherapy

Thumbnail

D2.184 - Trends in aeroallergen immunotherapy prescription

Thumbnail

D2.185 - Ultrarush honeybee venom immunotherapy in patients with monoclonal mast cell activation syndrome: two case reports

Thumbnail

D2.186 - Toxicity Assessment of Repeated Doses of Apis mellifera Venom for Immunotherapy

Thumbnail

D2.187 - Can the Conjunctival Allergen Provocation Test Improve Long-Term Adherence to Subcutaneous Allergen-Specific Immunotherapy?

Thumbnail

D2.188 - Low allergenicity of food allergen by Galactomannan Conjugation and immunotherapeutic efficacy of peanut-galactomannan conjugate in a mouse model of peanut allergy

Thumbnail

D2.189 - Eosinophilic Esophagitis Induced by Sublingual Immunotherapy (SLIT): A Rare but Emerging Side Effect

Thumbnail

D2.190 - Unmasking Autoimmunity: A Case of Thyroiditis Emerging After Allergy Immunotherapy

Thumbnail

D2.191 - Autoimmune Disease Unmasked by Allergic Immunotherapy: A Case of Systemic Lupus Erythematosus (SLE) After SCIT

Thumbnail

D2.192 - IgE-Mediated Immunotherapy-Induced Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Thumbnail

D2.193 - Oral Induction of Tolerance to Cow's Milk Protein Allergy in Omani Children: A Retrospective Analysis

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience

Thumbnail

D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab